Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

NCT07471789 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloblastic Leukaemia
Leukemia, T-Cell

Interventions

DRUG: CART84

Sponsor

Gyala Therapeutics

Collaborators

[object Object]